94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Alessio Bruni1*Vieri Scotti2Paolo Borghetti3Stefano Vagge4Salvatore Cozzi5Elisa D’Angelo1Niccolò Giaj Levra6Alessandra Fozza4Maria Taraborrelli7Gaia Piperno8Valentina Vanoni9Matteo Sepulcri10Marco Trovò11Valerio Nardone12Elisabetta Lattanzi13Said Bou Selman14Federica Bertolini15Davide Franceschini16Francesco Agustoni17Barbara Alicja Jereczek-Fossa8,18Stefano Maria Magrini3Lorenzo Livi2Frank Lohr1
Andrea Riccardo Filippi19- 1Radiotherapy Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy
- 2Department of Oncology, Radiation Therapy Unit, Careggi University Hospital, Florence, Italy
- 3Radiation Oncology Department, Spedali Civili and University of Brescia, Brescia, Italy
- 4Department of Radiation Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Martino, Genova, Italy
- 5Radiation Therapy Department, Arcispedale di Santa Maria Nuova IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Reggio Emilia, Italy
- 6Advanced Radiation Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Sacro Cuore Don Calabria Hospital, Verona, Italy
- 7Radiation Oncology Department, SS. Annunziata Hospital, “G. D’Annunzio” University of Chieti, Chieti, Italy
- 8Division of Radiotherapy, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) European Institute of Oncology, Milan, Italy
- 9Radiation Oncology Department, S. Chiara Hospital, Trento, Italy
- 10Radiation Oncology Unit, Veneto Institute of Oncology Istituto Oncologico Veneto (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy
- 11Radiation Oncology Department, Azienda Sanitaria Universitaria Integrata, Udine, Italy
- 12Radiotherapy Unit, “Ospedale del Mare”, Naples, Italy
- 13Radiotherapy Unit, University Hospital of Parma, Parma, Italy
- 14Department of Radiotherapy, Bolzano Hospital, Bolzano, Italy
- 15Medical Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy
- 16Department of Radiotherapy and Radiosurgery, Humanitas Research Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)–Humanitas Research Hospital, Milan, Italy
- 17Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy
- 18Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- 19Department of Radiation Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo and University of Pavia, Pavia, Italy
By Bruni A, Scotti V, Borghetti P, Vagge S, Cozzi S, D’Angelo E, Giaj Levra N, Fozza A, Taraborrelli M, Piperno G, Vanoni V, Sepulcri M, Trovò M, Nardone V, Lattanzi E, Bou Selman S, Bertolini F, Franceschini D, Agustoni F, Jereczek-Fossa BA, Magrini SM, Livi L, Lohr F and Filippi AR. (2021). Front. Oncol. 11:744956. doi: 10.3389/fonc.2021.744956
In the original article there was an error. The survival numbers were incorrect.
A correction has been made to Abstract:
“1-year PFS and OS were 83.5% (95%CI: 77.6-89.7) and 97.2% (95%CI: 94.6-99.9), respectively.”
“1-year PFS and OS were 65.5% (95%CI: 57.6-74.4) and 87.9% (95%CI: 82.26.6-93.9), respectively”
In the original article, there was an error. The survival numbers were incorrect.
A correction has been made to Results, Survival:
“PFS at 12, 18, and 24 months was 83.5% (95%CI: 77.6–89.7), 65.5 (95%CI: 57.6–74.4), and 53.1% (95%CI: 43.8–64.3), respectively. (Figure 1). OS at 12, 18, and 24 months was 97.2% (95%CI: 94.6– 99.9), 87.9% (95%CI: 82.26–93.9), and 79.3% (95%CI: 71.1–88.4), respectively (Figure 1).”
“PFS at 6, 12, and 18 months was 83.5% (95%CI: 77.6–89.7), 65.5% (95%CI: 57.6–74.4), and 53.1% (95%CI: 43.8–64.3), respectively. (Figure 1). OS at 6, 12, and 18 months was 97.2% (95%CI: 94.6– 99.9), 87.9% (95%CI: 82.26–93.9), and 79.3% (95%CI: 71.1–88.4), respectively (Figure 1)”
In the original article, there was an error. The survival numbers were incorrect.
A correction has been made to Discussion:
“12-month PFS was 83.5%, and OS 97.2%”
“12-month PFS was 65.5%, and OS 87.9%”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: chemoradiotherapy, immunotherapy, stage III, unresectable, NSCLC
Citation: Bruni A, Scotti V, Borghetti P, Vagge S, Cozzi S, D’Angelo E, Giaj Levra N, Fozza A, Taraborrelli M, Piperno G, Vanoni V, Sepulcri M, Trovò M, Nardone V, Lattanzi E, Bou Selman S, Bertolini F, Franceschini D, Agustoni F, Jereczek-Fossa BA, Magrini SM, Livi L, Lohr F and Filippi AR (2021) Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer. Front. Oncol. 11:802949. doi: 10.3389/fonc.2021.802949
Received: 27 October 2021; Accepted: 04 November 2021;
Published: 16 November 2021.
Edited and reviewed by:
Aditya Juloori, University of Chicago Medical Center, United StatesCopyright © 2021 Bruni, Scotti, Borghetti, Vagge, Cozzi, D’Angelo, Giaj Levra, Fozza, Taraborrelli, Piperno, Vanoni, Sepulcri, Trovò, Nardone, Lattanzi, Bou Selman, Bertolini, Franceschini, Agustoni, Jereczek-Fossa, Magrini, Livi, Lohr and Filippi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alessio Bruni, YnJ1bmkuYWxlc3Npb0Bhb3UubW8uaXQ=